214 related articles for article (PubMed ID: 12138377)
21. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
23. Economic effects of aspergillosis management in high-risk patients.
Leather H
Manag Care Interface; 2005 Apr; 18(4):46-52. PubMed ID: 15889762
[TBL] [Abstract][Full Text] [Related]
24. Combined therapy in treatment of murine infection by Fusarium solani.
Ruíz-Cendoya M; Mariné M; Guarro J
J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
[TBL] [Abstract][Full Text] [Related]
25. Voriconazole.
Naithani R; Kumar R
Indian Pediatr; 2005 Dec; 42(12):1207-12. PubMed ID: 16424557
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation.
Groll AH; Kolve H; Ehlert K; Paulussen M; Vormoor J
J Antimicrob Chemother; 2004 Jan; 53(1):113-4. PubMed ID: 14657088
[TBL] [Abstract][Full Text] [Related]
27. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Apisarnthanarak A; Little JR; Tebas P
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
[No Abstract] [Full Text] [Related]
28. Voriconazole: therapeutic review of a new azole antifungal.
Herbrecht R
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
[TBL] [Abstract][Full Text] [Related]
29. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Ullmann AJ; Heussel CP; Cornely OA
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
[No Abstract] [Full Text] [Related]
31. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
33. Antifungal chemotherapeutics.
Krcmery VC
Med Princ Pract; 2005; 14(3):125-35. PubMed ID: 15863983
[TBL] [Abstract][Full Text] [Related]
34. [The role of voriconazole in the treatment of emerging mycoses].
Pastor FJ; Guarro J
Rev Iberoam Micol; 2007 Sep; 24(3):228-32. PubMed ID: 17874861
[TBL] [Abstract][Full Text] [Related]
35. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
36. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
37. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
38. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
Maschmeyer G; Haas A
Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B.
Stanzani M; Vianelli N; Bandini G; Paolini S; Arpinati M; Bonifazi F; Giannini B; Agostinelli C; Baccarani M; Ricci P
J Infect; 2006 Dec; 53(6):e243-6. PubMed ID: 16584783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
